Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Total Current Liabilities data on record, last reported at $117.0 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $117.0 million; the TTM value through Sep 2025 reached $117.0 million, changed N/A, while the annual FY2024 figure was $80.6 million, 118.25% up from the prior year.
  • Total Current Liabilities reached $117.0 million in Q3 2025 per TARS's latest filing, up from $90.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $117.0 million in Q3 2025 and bottomed at $10.1 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $44.8 million, with a median of $26.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: grew 24.63% in 2022, then soared 249.28% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $11.5 million in 2021, then surged by 34.42% to $15.4 million in 2022, then surged by 139.39% to $36.9 million in 2023, then soared by 118.25% to $80.6 million in 2024, then skyrocketed by 45.2% to $117.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $117.0 million in Q3 2025, $90.3 million in Q2 2025, and $86.3 million in Q1 2025.